Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Strata Critical Medical ( (SRTA) ) is now available.
On January 30, 2026, Strata Critical Medical, Inc. and its subsidiaries entered into a secured, asset-based revolving credit agreement with JPMorgan Chase Bank for up to $30 million, maturing on January 30, 2029, with the potential to increase total capacity to $50 million, backed by first-priority liens on substantially all of the borrowers’ personal property under a new security agreement. Announced via press release on February 5, 2026, the undrawn facility is intended to fund working capital and general corporate purposes, with management emphasizing that it will primarily support Strata’s acquisition-driven growth strategy—particularly in clinical perfusion—while keeping the company’s owned aircraft fleet outside the collateral package to preserve future financing flexibility, a move that strengthens its balance sheet and acquisition capacity without immediately increasing leverage.
The most recent analyst rating on (SRTA) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Strata Critical Medical stock, see the SRTA Stock Forecast page.
Spark’s Take on SRTA Stock
According to Spark, TipRanks’ AI Analyst, SRTA is a Neutral.
Strata Critical Medical’s overall score is driven by financial challenges and valuation concerns, partially offset by positive earnings call insights and strategic corporate events.
To see Spark’s full report on SRTA stock, click here.
More about Strata Critical Medical
Strata Critical Medical, Inc. is a time-critical logistics and medical services provider to the U.S. healthcare industry, operating one of the nation’s largest air transport and surgical services networks for transplant hospitals and organ procurement organizations with an integrated “one call” solution for donor organ recovery. Its core offerings span air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant sector, alongside perfusion staffing and equipment solutions for cardiovascular surgery centers under the Trinity Medical Solutions and Keystone Perfusion brands.
Average Trading Volume: 945,515
Technical Sentiment Signal: Buy
Current Market Cap: $405.1M
Learn more about SRTA stock on TipRanks’ Stock Analysis page.